A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate
(2009) Expert Opinion on Pharmacotherapy — Vol. 10, n° 17, p. 2935-2937 (2009)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- A new drug combination regimen, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate (TDF), is described for the treatment of HIV-1 infection. This new drug combination regimen is applicable to the treatment of drug-naive HIV-1-infected patients. it extends the use of the drug combinations to a new class of anti-HIV drugs, i.e. raltegravir, targeted at a new site in the HIV-1 replicative cycle, namely the HIV-1 integrase. This opens new perspectives for the design of multiple drug combination regimens targeting different enzymes involved in HIV-1 replication, i.e. integrase and reverse transcriptase. These multiple (triple or quadruple) drug combinations should be aimed at once daily dosing.
- Affiliations
Citations
De Clercq, E. (2009). A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. Expert Opinion on Pharmacotherapy, 10(17), 2935-2937. https://doi.org/10.1517/14656560903418467 (Original work published 2009)